2019
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim D, Han J, Molina JR, Kim J, Arvis C, Ahn M, Majem M, Fidler MJ, Surmont V, de Castro G, Garrido M, Shentu Y, Emancipator K, Samkari A, Jensen EH, Lubiniecki GM, Garon EB. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Annals Of Oncology 2019, 30: 281-289. PMID: 30657853, PMCID: PMC6931268, DOI: 10.1093/annonc/mdy545.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBiopsyCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellDocetaxelFemaleFollow-Up StudiesHumansInternational AgenciesLung NeoplasmsMaleMiddle AgedParaffin EmbeddingPrognosisSpecimen HandlingSurvival RateYoung AdultConceptsTumor proportion scoreOS hazard ratioPD-L1 expressionProgression-free survivalPFS hazard ratioHazard ratioOverall survivalTumor samplesPD-L1PD-L1 tumor proportion scorePrespecified exploratory analysisPrimary end pointSubset of patientsCell lung cancerDeath 1 proteinArchival samplesDocetaxel 75KEYNOTE-010Pembrolizumab dosesRECIST v1.1Advanced NSCLCLung cancerProportion scorePatientsPrimary analysis
2008
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy
Giaccone G, Iacona RB, Fandi A, Janas M, Ochs JS, Herbst RS, Johnson DH. Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. Journal Of Cancer Research And Clinical Oncology 2008, 135: 467-476. PMID: 18787840, DOI: 10.1007/s00432-008-0466-3.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiopsyCarcinoma, Non-Small-Cell LungCell DivisionErbB ReceptorsGefitinibGene Expression Regulation, NeoplasticHumansImmunohistochemistryLung NeoplasmsNeoplasm StagingPlacebosPlatinum CompoundsPrognosisQuinazolinesSurvival AnalysisConceptsPlatinum-based chemotherapyCell lung cancerPrognostic factorsLung cancerFirst-line platinum-based chemotherapyEpidermal growth factor receptor stainingChemotherapy-naive patientsPlacebo-controlled trialCox regression analysisReceptor expression analysisStrong prognostic indicatorMembrane stainingEGFR expression correlatesSurvival benefitImproved survivalPrognostic effectGrowth patternPredictive factorsPrognostic indicatorReceptor stainingPoor survivalTreatment groupsEGFR PharmDxEGFR expressionGefitinib
2007
Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer
Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson BE. Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research 2007, 13: 6175-6181. PMID: 17947484, DOI: 10.1158/1078-0432.ccr-07-0460.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBiopsyCarcinoma, Non-Small-Cell LungDimerizationErbB ReceptorsFemaleFluorodeoxyglucose F18HumansLung NeoplasmsMaleMiddle AgedMutationPositron-Emission TomographyProtein Structure, TertiaryReceptor, ErbB-2Time FactorsTreatment OutcomeConceptsNon-small cell lung cancerProgression-free survival ratesCell lung cancerPositron emission tomographyLung cancerRecurrent non-small cell lung cancerHumanized monoclonal anti-HER2 antibodyGrade 4 adverse eventsGrade 4 cardiac toxicityPrimary efficacy end pointEmission tomographyEfficacy end pointPhase II trialResponse Evaluation CriteriaMonoclonal anti-HER2 antibodyOverall response rateMetabolic responseTumor glucose metabolismAnti-HER2 antibodyStable diseaseII trialAdverse eventsCardiac toxicityPharmacodynamic markersCore biopsy
2003
Surrogate markers in antiangiogenesis clinical trials
Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Surrogate markers in antiangiogenesis clinical trials. British Journal Of Cancer 2003, 89: 8-14. PMID: 12838293, PMCID: PMC2394225, DOI: 10.1038/sj.bjc.6601035.Peer-Reviewed Original Research
2001
Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin
Herbst R, Lee A, Tran H, Abbruzzese J. Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin. Current Oncology Reports 2001, 3: 131-140. PMID: 11177745, DOI: 10.1007/s11912-001-0013-8.Peer-Reviewed Original ResearchConceptsPhase I trialI trialClinical studiesHuman endostatinTumor vasculatureSolid tumor malignanciesAnti-angiogenic agentsAnti-angiogenic mechanismAnti-angiogenic compoundsToxic cancer treatmentsAdvanced diseaseBlood vessel supplyCenter trialMinimal diseaseTumor sizeNovel agentsSurrogate endpointsNew agentsSide effectsBiologic mechanismsSingle agentAngiogenesis inhibitorsGrowth-inhibiting moleculesNon-toxic agentsTumor growth